Clinical Trials Browser

Recurrence × Cetuximab × Head & Neck × Clear all

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Squamous Cell, Neoplasm Metastasis, Recurrence

NCT03082534 2026-01-28

Pembrolizumab Combined With Cetuximab for Treatment of Recurrent/Metastatic Head & Neck Squamous Cell Carcinoma

Squamous Cell Carcinoma of Head and Neck, Head and Neck Neoplasms, Hypopharyngeal Neoplasms, Laryngeal Neoplasms, Mouth Neoplasms, Nasopharyngeal Neoplasms, Neoplasm Metastasis, Oropharyngeal Neoplasms, Recurrence

NCT01552434 2025-10-14

Bevacizumab and Temsirolimus Alone or in Combination With Valproic Acid or Cetuximab in Treating Patients With Advanced or Metastatic Malignancy or Other Benign Disease

Phase 1 Active not recruiting

155 enrolled

BreastCNSGenitourinaryHead & NeckLymphoidMyeloidSarcoma

Breast Neoplasms, Carcinoma, Transitional Cell, Endocrine Gland Neoplasms, Castleman Disease, Mouth Neoplasms, Neoplasm Metastasis, Neoplasms, Pharyngeal Neoplasms, Recurrence, Sarcoma, Soft Tissue Neoplasms, Thyroid Neoplasms, Urologic Neoplasms, Neurofibromatosis 2, Lymphangioleiomyomatosis, Neoplasms, Mesothelial, Erdheim-Chester Disease

NCT02624128 2023-11-13

V-CHANCE

Phase 2 Unknown

39 enrolled

Head & Neck

Squamous Cell Carcinoma of Head and Neck, Head and Neck Neoplasms, Neoplasm Metastasis, Recurrence

NCT05260671 2023-10-18

Penpulimab in Combination With Cetuximab as First-line Treatment in R/M SCCHN

Phase 2 Recruiting

48 enrolled

Head & Neck

Head and Neck Neoplasms, Neoplasm Metastasis, Recurrence

NCT01864772 2022-08-19

ELANFIT

Phase 2 Completed

85 enrolled

Head & Neck

Squamous Cell Carcinoma of Head and Neck, Neoplasm Metastasis, Recurrence

NCT04464967 2021-05-12

Safety and Preliminary Efficacy of SNK01 in Combination With Trastuzumab or Cetuximab in Subjects With Advanced HER2 or EGFR Cancers

Phase 1/2 Withdrawn

BreastGastrointestinalGenitourinaryGynecologicHead & NeckSarcomaThoracic

Squamous Cell Carcinoma of Head and Neck, Urinary Bladder Neoplasms, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Uterine Cervical Neoplasms, Esophageal Neoplasms, Neoplasm Metastasis, Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Recurrence, Sarcoma, Stomach Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms, Triple Negative Breast Neoplasms

NCT03887442 2021-01-07

EXTAX

Phase 2 Terminated

17 enrolled 8 charts

Head & Neck

Head and Neck Neoplasms, Neoplasm Metastasis, Recurrence

NCT02124707 2020-08-12

Weekly Carboplatin, Paclitaxel and Cetuximab Treatment for Patients With Recurrent or Metastatic SCCHN

Phase 2 Completed

14 enrolled 17 charts

Head & Neck

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Squamous Cell, Head and Neck Neoplasms, Neoplasm Metastasis, Recurrence

NCT02350712 2018-09-11

Patritumab With Cetuximab and a Platinum Containing Therapy for Patients With Head and Neck Cancer

Phase 1 Completed

15 enrolled

Head & Neck

Squamous Cell Carcinoma of Head and Neck, Recurrence

NCT01488318 2018-01-05

Cetuximab and Dasatinib in Recurrent Squamous Cell Carcinoma

Phase 2 Terminated

21 enrolled 8 charts

Head & Neck

Squamous Cell Carcinoma of Head and Neck, Neoplasm Metastasis, Recurrence

NCT01794845 2017-05-11

Cetuximab + Taxotere With Low Dose Fractionated Radiation for Head and Neck Carcinoma

Phase 2 Terminated

5 enrolled 9 charts

Head & Neck

Carcinoma, Squamous Cell, Head and Neck Neoplasms, Recurrence

NCT01040832 2017-01-30

EMD 1201081 in Combination With Cetuximab in Second-Line Cetuximab-Naïve Subjects With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck

Phase 2 Completed

107 enrolled 12 charts

Head & Neck

Head and Neck Neoplasms, Recurrence

NCT01427205 2013-04-05

Phase II Study of Cetuximab With or Without OSI-906 in Head and Neck Squamous Cell Carcinoma (HNSCC)

Phase 2 Withdrawn

Head & Neck

Squamous Cell Carcinoma of Head and Neck, Head and Neck Neoplasms, Laryngeal Diseases, Neoplasm Metastasis, Recurrence

Clinical Trials

FIERCE-HN

Pembrolizumab Combined With Cetuximab for Treatment of Recurrent/Metastatic Head & Neck Squamous Cell Carcinoma

Bevacizumab and Temsirolimus Alone or in Combination With Valproic Acid or Cetuximab in Treating Patients With Advanced or Metastatic Malignancy or Other Benign Disease

V-CHANCE

Penpulimab in Combination With Cetuximab as First-line Treatment in R/M SCCHN

ELANFIT

Safety and Preliminary Efficacy of SNK01 in Combination With Trastuzumab or Cetuximab in Subjects With Advanced HER2 or EGFR Cancers

EXTAX

Weekly Carboplatin, Paclitaxel and Cetuximab Treatment for Patients With Recurrent or Metastatic SCCHN

Patritumab With Cetuximab and a Platinum Containing Therapy for Patients With Head and Neck Cancer

Cetuximab and Dasatinib in Recurrent Squamous Cell Carcinoma

Cetuximab + Taxotere With Low Dose Fractionated Radiation for Head and Neck Carcinoma

EMD 1201081 in Combination With Cetuximab in Second-Line Cetuximab-Naïve Subjects With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck

Phase II Study of Cetuximab With or Without OSI-906 in Head and Neck Squamous Cell Carcinoma (HNSCC)